Siegfried opens new global R&D Center for Drug Substances in Evionnaz – Biotech Investments

Media Release
Zofingen, November 19, 2024

Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), inaugurated its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland. The 4,500m² R&D Center houses advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

Together with the R&D Center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried’s global Drug Substances network. With workspaces for over 100 highly skilled specialists and 40 new jobs created, the R&D Center strengthens Siegfried’s development excellence in phase II and III supporting the company’s EVOLVE⁺ strategy.

Marcel Imwinkelried, CEO of Siegfried: “The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our EVOLVE⁺ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector.”

• Siegfried inaugurated its new state-of-the-art R&D Center for Drug Substances in Evionnaz (Switzerland)
• The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain, France, Malta, the USA and China. In 2023, the company achieved sales of CHF 1.272 billion and employed on 31.12.2023 more than 3700 people at twelve sites on three continents. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services. 

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.